Popup content
Intended for US Healthcare Professionals only
For patients and caregivers
Specialty (Select one)
Access Support
Every case is different. We’re dedicated to helping patients who are prescribed Acthar® Gel (repository corticotropin injection) get the treatment they need.
Monday through Friday, 8 AM to 9 PM ET
Saturday, 9 AM to 2 PM ET

Acthar Patient Support works closely with your office throughout the insurance approval process, keeping patients informed along the way. If assistance is needed, the following options may be available:

If your patients have commercial or private insurance, they may be eligible for the Acthar Commercial Co-pay Program. The program provides the following:

  • $0 co-pay for eligible patients (See Terms and Conditions below)
  • Enrollment over the phone during the Acthar welcome call or anytime they are speaking with their Case Manager
  • Automatic processing by the Acthar Specialty Pharmacy with no attempt to collect a co-pay

If patients do not have insurance coverage, they may be able to receive assistance options through the Acthar Patient Assistance Program*:

  • Mallinckrodt provides Acthar at no cost to eligible patients with a valid, on-label prescription for Acthar who have no insurance, are underinsured, or are rendered uninsured
  • Their Case Manager will transfer them to the Acthar Patient Assistance Program to determine eligibility
  • This program is administered via a third-party organization

*Acthar Patient Assistance Program eligibility criteria:

  • Valid Acthar prescription for an FDA-approved indication
  • Permanent US resident
  • Household income at or below 700% of the Federal Poverty Level
  • Patients may be subject to random income verification to determine eligibility

Co-Pay Program Terms and Conditions:

  • Patient must have a valid Acthar® Gel prescription for an FDA-approved, on-label indication.
  • Patient must be a permanent US resident. Offer is good only in the United States and US Territories.
  • Patient (or patient’s legal representative) must be 18 years of age or older to opt into program.
  • This program is valid for eligible privately and commercially insured patients.
  • This program is not valid for patients covered by Medicare, Medicare D, Medicare Advantage Plans, Medicaid plans (including Medicaid patients enrolled in a qualified health plan purchased through a health insurance exchange [marketplace], TRICARE, Department of Defense (DOD), Veterans Affairs (VA), or any other state or federal medical or pharmacy benefit program.
  • The Acthar Commercial Co-pay Program provides drug co-pay assistance of up to $25,000 per calendar year for each eligible patient.
  • The program covers out-of-pocket costs for Acthar® Gel only. The program will not and shall not be applied toward the cost of any other product, healthcare provider service, supply charges or other treatment costs.
  • This program does not constitute prescription drug coverage or insurance and is not intended to substitute for such coverage. This program is not valid for uninsured patients and cannot be used as primary insurance.
  • The offer is not valid for drug costs that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs, which reimburse you for the entire cost of your prescription drugs.
  • Enrollment in the co–pay assistance program does not guarantee assistance. Whether an expense is eligible for the copay benefit will be determined at the time the benefit is paid. Eligible co-pay expenses must be in connection with a separately paid claim for Acthar® Gel which is otherwise covered by a private/commercial insurance plan.
  • If your insurance status changes, you must notify us prior to fulfilling your next prescription of Acthar® Gel.
  • This program offer is limited to 1 membership per person and is not transferable and cannot be combined with any other co-pay assistance program, free trial, discount, prescription savings card, or other offer.
  • Patients should consult their insurance provider concerning any limitations that may apply to this program under their insurance policy. Patients are responsible for any co-payment or coinsurance costs above and beyond the program’s annual maximum benefit.
  • The program is not available where prohibited by law.
  • Mallinckrodt reserves the right to rescind, revoke, or amend the co-pay assistance program at any time without notice.
  • Patient will be subject to ineligibility from the Program for violation of these Terms & Conditions.
Supporting Patient Rights

Acthar Patient Support offers help so patients can raise their voice and advocate for their own health.

See How We Can Help
resource form icon

Forms & Documents

Materials to support your practice as you prescribe Acthar® Gel (repository corticotropin injection) and manage prior authorizations and appeals

View Resources

Need support now or want to request

injection training for a patient?

Need support now or want to request injection training for a patient?

Acthar Patient Support is available at
1-888-435-2284

Acthar Patient Support is available at

1-888-435-2284

Monday through Friday, 8 AM to 9 PM ET

Saturday, 9 AM to 2 PM ET

See more +

IMPORTANT SAFETY INFORMATION

Contraindications

  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
  • Acthar is contraindicated where congenital infections are suspected in infants
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

Warnings and Precautions

  • The adverse effects of Acthar are related primarily to its steroidogenic effects
  • Acthar may increase susceptibility to new infection or reactivation of latent infections
  • Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment
  • Cushing’s syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
  • Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored

INDICATIONS

Acthar® Gel (repository corticotropin injection) is indicated for:

  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
  • Monotherapy for the treatment of infantile spasms in infants and children under 2 years of age
  • The treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease
  • Inducing a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus
  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
  • The treatment of symptomatic sarcoidosis
  • Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low‐dose maintenance therapy), ankylosing spondylitis
  • Treatment of severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation

IMPORTANT SAFETY INFORMATION

Contraindications

  • Acthar should never be administered intravenously
  • Administration of live or live attenuated vaccines is contraindicated in patients receiving immunosuppressive doses of Acthar
  • Acthar is contraindicated where congenital infections are suspected in infants
  • Acthar is contraindicated in patients with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, recent surgery, history of or the presence of a peptic ulcer, congestive heart failure, uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction or sensitivity to proteins of porcine origins

INDICATIONS

  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus
  • Monotherapy for the treatment of infantile spasms in infants and children under 2 years of age
  • The treatment of acute exacerbations of multiple sclerosis in adults. Controlled clinical trials have shown Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease
  • Inducing a diuresis or a remission of proteinuria in nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus
  • Treatment during an exacerbation or as maintenance therapy in selected cases of systemic dermatomyositis (polymyositis)
  • The treatment of symptomatic sarcoidosis
  • Adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low‐dose maintenance therapy), ankylosing spondylitis
  • Treatment of severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: keratitis, iritis, iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, anterior segment inflammation

Warnings and Precautions

  • The adverse effects of Acthar are related primarily to its steroidogenic effects
  • Acthar may increase susceptibility to new infection or reactivation of latent infections
  • Suppression of the hypothalamic-pituitary-axis (HPA) may occur following prolonged therapy with the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by tapering of the dose when discontinuing treatment. During recovery of the adrenal gland patients should be protected from the stress (e.g. trauma or surgery) by the use of corticosteroids. Monitor patients for effects of HPA suppression after stopping treatment
  • Cushing’s syndrome may occur during therapy but generally resolves after therapy is stopped. Monitor patients for signs and symptoms
  • Acthar can cause elevation of blood pressure, salt and water retention, and hypokalemia. Blood pressure, sodium and potassium levels may need to be monitored
  • Acthar often acts by masking symptoms of other diseases/disorders. Monitor patients carefully during and for a period following discontinuation of therapy
  • Acthar can cause GI bleeding and gastric ulcer. There is also an increased risk for perforation in patients with certain gastrointestinal disorders. Monitor for signs of bleeding
  • Acthar may be associated with central nervous system effects ranging from euphoria, insomnia, irritability, mood swings, personality changes, and severe depression, and psychosis. Existing conditions may be aggravated
  • Patients with comorbid disease may have that disease worsened. Caution should be used when prescribing Acthar in patients with diabetes and myasthenia gravis
  • Prolonged use of Acthar may produce cataracts, glaucoma and secondary ocular infections. Monitor for signs and symptoms
  • Acthar is immunogenic and prolonged administration of Acthar may increase the risk of hypersensitivity reactions. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH activity
  • There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis of the liver
  • Long-term use may have negative effects on growth and physical development in children. Monitor pediatric patients
  • Decrease in bone density may occur. Bone density should be monitored for patients on long-term therapy
  • Pregnancy Class C: Acthar has been shown to have an embryocidal effect and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus

Adverse Reactions

  • Common adverse reactions for Acthar are similar to those of corticosteroids and include fluid retention, alteration in glucose tolerance, elevation in blood pressure, behavioral and mood changes, increased appetite and weight gain
  • Specific adverse reactions reported in IS clinical trials in infants and children under 2 years of age included: infection, hypertension, irritability, Cushingoid symptoms, constipation, diarrhea, vomiting, pyrexia, weight gain, increased appetite, decreased appetite, nasal congestion, acne, rash, and cardiac hypertrophy. Convulsions were also reported, but these may actually be occurring because some IS patients progress to other forms of seizures and IS sometimes mask other seizures, which become visible once the clinical spasms from IS resolve

Other adverse events reported are included in the full Prescribing Information.


Please see full Prescribing Information.


For parents and caregivers of IS patients, please also see Medication Guide.



tool options button
tool options button